Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine University Hospital, Moorenstrasse 5, 40225 Düsseldorf, Germany.
Biochem Biophys Res Commun. 2013 Feb 15;431(3):428-32. doi: 10.1016/j.bbrc.2012.12.153. Epub 2013 Jan 16.
Hepatocyte-growth factor (HGF) is expressed by glioblastomas and contributes to their growth, migration and invasion. HGF also mediates migration of mesenchymal stem cells (MSC) to sites of apoptotic cell death. Moreover, MSC show tropism for glioblastomas, which is exploited in gene therapy to deliver the therapeutics to the tumor cells. Here, we have studied whether HGF contributes to the recruitment of MSC by glioblastoma cells and whether aminolaevulinic acid-mediated photodynamic therapy (ALA/PDT), a novel therapeutic approach that induces apoptosis in glioblastoma cells, affects HGF release and this migratory response. MSC expressed the HGF receptor MET and migrated towards U87 and U251 glioblastoma spheroids. Migration increased significantly when spheroids were subjected to ALA/PDT, which was associated with induction of apoptosis and up-regulation of HGF. Neutralizing HGF resulted in significant inhibition of MSC migration towards untreated as well as ALA/PDT-treated spheroids. Thus, glioblastoma cells express HGF, which contributes to the attraction of MSC. ALA/PDT induces apoptosis and augments HGF release causing enhanced MSC migration towards the tumor cells. ALA/PDT may therefore be exploited to improve targeting of MSC delivered gene therapy, but it may also constitute a risk in terms of beneficial effects for the tumor.
肝细胞生长因子 (HGF) 由胶质母细胞瘤表达,并有助于其生长、迁移和侵袭。HGF 还介导间充质干细胞 (MSC) 向细胞凋亡死亡部位的迁移。此外,MSC 对胶质母细胞瘤具有趋化性,这在基因治疗中被用来将治疗剂递送到肿瘤细胞。在这里,我们研究了 HGF 是否有助于胶质母细胞瘤细胞招募 MSC,以及氨基酮戊酸介导的光动力疗法 (ALA/PDT) 是否会影响 HGF 释放和这种迁移反应,ALA/PDT 是一种诱导胶质母细胞瘤细胞凋亡的新型治疗方法。MSC 表达 HGF 受体 MET,并向 U87 和 U251 胶质母细胞瘤球体迁移。当球体接受 ALA/PDT 时,迁移显著增加,这与诱导凋亡和上调 HGF 有关。中和 HGF 导致 MSC 向未处理和 ALA/PDT 处理的球体的迁移显著抑制。因此,胶质母细胞瘤细胞表达 HGF,有助于吸引 MSC。ALA/PDT 诱导凋亡并增加 HGF 释放,导致 MSC 向肿瘤细胞的迁移增强。因此,ALA/PDT 可用于改善 MSC 递送基因治疗的靶向性,但从肿瘤的有益效果来看,它也可能构成风险。